# US 2022/0264871 A1 · Cell cryopreservation solution and method for cryopreserving cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0264871 A1
- Document ID: US20220264871A1
- Status: Published application
- Kind: A1
- Application number: 17/533,215
- Filed: 2021-11-23
- Published: 2022-08-25
- Earliest claimed: 2021-01-11
- Assignees: Boe Regenerative Medicine Technology Co., Ltd.; Boe Technology Group Co., Ltd.
- Applicants: Boe Regenerative Medicine Technology Co., Ltd.; Boe Technology Group Co., Ltd.
- Inventors: Donghua LIU; Dehua CHANG; Xuejiao DONG; Shuai LIU; Yufei ZHAO; YANG LIU; Yuandong LIU; Xiaotong YANG
- Web page: https://patentgrep.com/patent/US20220264871A1

## CPC

- A01N 1/125: Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
- A01N 1/122: Preservation or perfusion media
- A01N 1/162: Temperature processes, e.g. following predefined temperature changes over time
- C12N 5/0634: {Cells from the blood or the immune system}
- C12N 2500/62: DMSO
- C12N 2523/00: Culture process characterised by temperature
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method for cryopreserving cells, a cell cryopreservation solution and a composition are provided. The method includes: providing a suspension for the cells to be cryopreserved in a cell cryopreservation solution; and cryopreserving the suspension. The cell cryopreservation solution includes dimethyl sulfoxide, plasma, citric acid, sodium citrate, potassium dihydrogen phosphate or sodium dihydrogen phosphate, glucose and adenine.

## Claims

### Claim 1

A method for cryopreserving cells, comprising:
providing a suspension for the cells to be cryopreserved in a cell cryopreservation solution; and
cryopreserving the suspension,
wherein the cell cryopreservation solution comprises dimethyl sulfoxide, plasma, citric acid, sodium citrate, potassium dihydrogen phosphate or sodium dihydrogen phosphate, glucose and adenine.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cell cryopreservation solution comprises one or more of the following features:
dimethyl sulfoxide at a volume fraction of 5% to 15%,
plasma at a volume fraction of 50% to 90%,
citric acid at a mass volume fraction of 0.05% to 0.09%,
sodium citrate at a mass volume fraction of 0.40% to 0.70%,
potassium dihydrogen phosphate or sodium dihydrogen phosphate at a mass volume fraction of 0.03% to 0.06%,
glucose at a mass volume fraction of 0.50% to 1.0%, and
adenine at a mass volume fraction of 0.005% to 0.01%.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cell cryopreservation solution comprises plasma at a volume fraction of 65% to 75%.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cell cryopreservation solution further comprises calcium gluconate.

### Claim 5 (depends on 4)

The method of claim 4, wherein the cell cryopreservation solution further comprises calcium gluconate at a mass volume fraction of 0.01% to 0.8%.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cryopreserving the suspension comprises:
subjecting the suspension to a low-temperature standing treatment, wherein the low-temperature standing treatment is carried out at a temperature of −78° C. to −82° C. for a time period within 14 days; and
rapid-freezing the suspension after the low-temperature standing treatment, wherein the rapid-freezing treatment is carried out in liquid nitrogen.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cells to be cryopreserved are human peripheral blood mononuclear cells.

### Claim 8 (depends on 7)

The method of claim 7, wherein the cells to be cryopreserved are obtained by a process comprising:
mixing human peripheral blood with a reagent comprising citric acid at a mass volume fraction of 0.2% to 0.5%, sodium citrate at a mass volume fraction of 2% to 4%, potassium dihydrogen phosphate or sodium dihydrogen phosphate at a mass volume fraction of 0.1% to 0.3%, glucose at a mass volume fraction of 2.5% to 5%, and adenine at a mass volume fraction of 0.02% to 0.05%, wherein the volume ratio of the human peripheral blood to the reagent is 200:(25-30);
subjecting the mixed product to density gradient centrifugation to obtain an intermediate cell layer; and
resuspending and centrifuging the intermediate cell layer in a new centrifuge tube to obtain the cells to be cryopreserved.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cell cryopreservation solution is obtained by a process comprising:
mixing human peripheral blood with a reagent comprising citric acid at a mass volume fraction of 0.2% to 0.5%, sodium citrate at a mass volume fraction of 2% to 4%, potassium dihydrogen phosphate or sodium dihydrogen phosphate at a mass volume fraction of 0.1% to 0.3%, glucose at a mass volume fraction of 2.5% to 5%, and adenine at a mass volume fraction of 0.02% to 0.05%, wherein the volume ratio of the human peripheral blood to the reagent is 200:(25-30);
subjecting the mixed product to density gradient centrifugation treatment to obtain a supernatant; and
mixing the supernatant with a predetermined amount of DMSO to obtain the cell cryopreservation solution.

### Claim 10 (depends on 7)

The method of claim 7, wherein the providing the suspension for the cells to be cryopreserved in a cell cryopreservation solution comprises:
mixing human peripheral blood with a reagent comprising citric acid at a mass volume fraction of 0.2% to 0.5%, sodium citrate at a mass volume fraction of 2% to 4%, potassium dihydrogen phosphate or sodium dihydrogen phosphate at a mass volume fraction of 0.1% to 0.3%, glucose at a mass volume fraction of 2.5% to 5%, and adenine at a mass volume fraction of 0.02% to 0.05%, wherein the volume ratio of the human peripheral blood to the reagent is 200:(25-30);
subjecting the mixed product to density gradient centrifugation to obtain an intermediate cell layer and a supernatant;
resuspending and centrifuging the intermediate cell layer in a new centrifuge tube to obtain the cells to be cryopreserved;
mixing the supernatant with a predetermined amount of DMSO to obtain the cryopreservation solution; and
resuspending the cells to be cryopreserved in the cryopreservation solution to obtain the suspension.

### Claim 11 (depends on 10)

The method of claim 10, wherein the density gradient centrifugation is performed within 8 hours after mixing of the human peripheral blood and the reagent.

### Claim 12 (depends on 10)

The method of claim 10, wherein the method further comprises mixing the supernatant with a predetermined amount of calcium gluconate.

### Claim 13

A cell cryopreservation solution, comprising dimethyl sulfoxide, plasma, citric acid, sodium citrate, potassium dihydrogen phosphate or sodium dihydrogen phosphate, glucose and adenine.

### Claim 14 (depends on 13)

The cell cryopreservation solution of claim 13, wherein the cell cryopreservation solution comprises one or more of the following features:
dimethyl sulfoxide at a volume fraction of 5% to 15%,
plasma at a volume fraction of 50% to 90%,
citric acid at a mass volume fraction of 0.05% to 0.09%,
sodium citrate at a mass volume fraction of 0.40% to 0.70%,
potassium dihydrogen phosphate or sodium dihydrogen phosphate at a mass volume fraction of 0.03% to 0.06%,
glucose at a mass volume fraction of 0.50% to 1.0%, and
adenine at a mass volume fraction of 0.005% to 0.01%.

### Claim 15 (depends on 14)

The cell cryopreservation solution of claim 14, wherein the cell cryopreservation solution comprises plasma at a volume fraction of 65% to 75%.

### Claim 16 (depends on 13)

The cell cryopreservation solution of claim 13, wherein the cell cryopreservation solution further comprises calcium gluconate.

### Claim 17 (depends on 16)

The cell cryopreservation solution of claim 16, wherein the cell cryopreservation solution further comprises calcium gluconate at a mass volume fraction of 0.01% to 0.8%.

### Claim 18

A composition, comprising a cell cryopreservation solution and cells cryopreserved in the cell cryopreservation solution, wherein the cell cryopreservation solution comprises dimethyl sulfoxide, plasma, citric acid, sodium citrate, potassium dihydrogen phosphate or sodium dihydrogen phosphate, glucose and adenine, and further comprises calcium gluconate.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the cells and the plasma in the cryopreservation solution are derived from the same organism.

### Claim 20 (depends on 18)

The composition of claim 18, wherein the cells are human peripheral blood mononuclear cells.
